

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

FAMY CARE LIMITED  
Petitioner

v.

ALLERGAN, INC.  
Patent Owner

U.S. Patent No. 8,642,556 B2 to Acheampong *et al.*

Issue Date: February 4, 2014

Title: Methods of Providing Therapeutic Effects Using Cyclosporin Components

---

*Inter Partes* Review Trial No. 2017-00570

---

**Petition for *Inter Partes* Review of U.S. Patent No. 8,642,556**

***Mail Stop "PATENT BOARD"***

Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

TABLE OF CONTENTS

EXHIBIT LIST PURSUANT TO 37 C.F.R. § 42.63(e) AND TABLE OF ABBREVIATIONS ..... iv

I. INTRODUCTION. .... 2

II. MANDATORY NOTICES (37 C.F.R. § 42.8(a)(1)). .... 4

    A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)). ....4

    B. Related Matters (37 C.F.R. § 42.8(b)(2)). ....4

    C. Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3)). ....5

    D. Service Information (37 C.F.R. § 42.8(b)(4)). ....6

III. GROUNDS FOR STANDING (37 C.F.R. § 42.104(a)). .... 6

IV. SPECIFIC IDENTIFICATION OF CHALLENGE (37 C.F.R. § 42.104(b)). .... 6

V. OVERVIEW OF THE '556 PATENT. .... 7

    A. '556 Patent Claims. ....7

    B. '556 Patent Prosecution History.....9

VI. PERSON OF ORDINARY SKILL IN THE ART. .... 10

VII. STATE OF THE ART AS OF SEPTEMBER 15, 2003. .... 11

VIII. PRIOR ART..... 13

    A. Ding '979 (EX1006)..... 13

    B. Sall (EX1007)..... 15

    C. Acheampong (EX1008)..... 15

    D. Glonek (EX1009). .... 16

**Petition for *Inter Partes* Review of U.S. Patent No. 8,642,556 B2**

IX. CLAIM CONSTRUCTION. .... 17

A. “therapeutically effective,” “effective amount,” “overall efficacy,” “therapeutic effectiveness” ..... 17

B. “buffer” ..... 18

C. “substantially no detectable concentration” ..... 18

D. “adverse events” and “side effects” ..... 19

E. “breaks down” ..... 20

X. EXPLANATION OF UNPATENTABILITY GROUNDS. .... 21

A. Ding ’979 Claim Chart. .... 21

B. Ground 1: Claims 1-20 are Unpatentable Under 35 U.S.C. § 102 by Ding ’979..... 28

1. Claims 1-10 and 12-13..... 28

a. Preamble and Dry Eye Efficacy Elements ..... 29

b. CsA and Castor Oil Elements ..... 30

c. Additional Composition Elements ..... 31

d. Comparison Elements ..... 32

e. Ding ’979 taught the entire claimed Composition II formulation..... 33

f. Therapeutic effectiveness ..... 35

2. Claim 14..... 37

3. Claims 15-17..... 38

4. Claims 11 and 18-20. .... 39

C. Ground 2: Claims 1-20 Are Unpatentable Under 35 U.S.C. § 103 in View of Ding ’979 and Sall. .... 40

1. Claims 1-10 and 12-13..... 41

**Petition for *Inter Partes* Review of U.S. Patent No. 8,642,556 B2**

a. Preamble and Dry Eye Efficacy Elements: ..... 41

b. CsA Elements (claims 1 and 13) ..... 43

c. Castor Oil Elements (independent claims 1 and 13)44

d. Additional Composition Elements: ..... 47

e. Efficacy..... 48

2. Claim 14..... 50

3. Claims 15-17..... 51

4. Claims 11 and 18-20. .... 53

D. Ground 3: Claims 14 and 19 Are Unpatentable Under 35 U.S.C. § 103 in View of Ding ‘979, Sall, and Glonek. .... 54

E. Ground 4: Claims 11 and 18-20 Are Unpatentable Under 35 U.S.C. § 103 in View of Ding ‘979, Sall, and Acheampong..... 55

F. Ground 5: Claim 19 is Unpatentable Under 35 U.S.C. § 103 in View of Ding ‘979, Sall, Glonek and Acheampong. .... 57

XI. ALLERGAN’S ALLEGED SECONDARY CONSIDERATIONS DO NOT OVERCOME PETITIONER’S STRONG SHOWING OF OBVIOUSNESS ..... 58

A. No Unexpected Results. .... 61

1. Schiffman Exhibit B ..... 62

2. Schiffman Exhibit C/Attar Exhibit B..... 67

3. Schiffman Exhibit D ..... 69

4. Schiffman Exhibits E and F/Attar Exhibits D and E. .... 74

B. Near-Simultaneous Invention..... 78

XII. CONCLUSION..... 79

XIII. CERTIFICATE OF COMPLIANCE ..... 80

**EXHIBIT LIST PURSUANT TO 37 C.F.R. § 42.63(e) AND  
TABLE OF ABBREVIATIONS**

<b>Exhibit</b>	<b>Description of Exhibit</b>
<b>1001</b>	U.S. Patent No. 8,642,556 B2 to Acheampong et al., filed August 14, 2013 (“the ’556 patent”)
<b>1002</b>	Declaration of Dr. Peter Kador
<b>1003</b>	Declaration of Dr. Michael A. Lemp
<b>1004</b>	File history of U.S. Patent No. 8,642,556 to Acheampong et al., filed August 14, 2013 (“’556 patent FH”)
<b>1005</b>	File history of U.S. Patent Application No. 10/927,857 to Acheampong et al., filed August 27, 2004 (“’857 application FH”)
<b>1006</b>	U.S. Patent No. 5,474,979 to Ding et al., filed May 17, 1994 (“Ding ’979”)
<b>1007</b>	K. Sall et al., <i>Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease</i> , 107 OPTHALMOLOGY 631 (2000) (“Sall”)
<b>1008</b>	A. Acheampong et al., <i>Cyclosporine Distribution into the Conjunctiva, Cornea, Lacrimal Gland, and Systemic Blood Following Topical Dosing of Cyclosporine to Rabbit, Dog, and Human Eyes, in 2 LACRIMAL GLAND, TEAR FILM, &amp; DRY EYE SYNDROMES 1001</i> (David A. Sullivan et al. eds., 1998) (“Acheampong”)
<b>1009</b>	U.S. Patent No. 5,578,586 to Glonek et al., filed February 4, 1994 (“Glonek”)
<b>1010</b>	U.S. Patent No. 5,981,607 to Ding et al., filed January 20, 1998 (“Ding ’607”)
<b>1011</b>	R. Kaswan, <i>Intraocular Penetration of Topically Applied Cyclosporine</i> , 20 TRANSPL. PROC. 650 (1988) (“Kaswan”)
<b>1012</b>	K. Kunert et al., <i>Analysis of Topical Cyclosporine Treatment of Patients with Dry Eye Syndrome</i> , 118 ARCH OPHTHALMOL 1489 (2000) (“Kunert”)
<b>1013</b>	PHYSICIANS’ DESK REFERENCE FOR OPTHALMOLOGY 13-18 (Medical Economics Co., 27th ed. 1999) (“Ophthalmic PDR”)
<b>1014</b>	K. Turner et al., <i>Interleukin-6 Levels in the Conjunctival Epithelium of Patients with Dry Eye Disease Treated with Cyclosporine Ophthalmic Emulsion</i> , 19 CORNEA 492 (2000) (“Turner”)
<b>1015</b>	D. Stevenson et al., <i>Efficacy and Safety of Cyclosporin A Ophthalmic</i>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.